Back to results
US 11,590,201 B2Granted
Endoglin peptides to treat fibrotic diseases
AssigneeAcceleron Pharma Inc.
InventorsAsya Grinberg, Roselyne Castonguay, Eric Werner, Ravindra Kumar
Life of this patent
Estimating the term…
Abstract
In certain aspects, the present disclosure relates to the insight that a polypeptide comprising a truncated, ligand-binding portion of the extracellular domain of endoglin (ENG) polypeptide may be used to treat fibrotic disorders.
Claims16
A method of treating liver fibrosis in a patient in need thereof, the method comprising administering to the patient an effective amount of an endoglin fusion protein, wherein the endoglin fusion protein comprises:
- (a) a first portion comprising an endoglin polypeptide consisting of amino acids 26-346 of SEQ ID NO:
- 1, and
- (b) a second heterologous portion comprising an immunoglobulin Fc domain.
Dependencies are inferred from the claim text.